AACR Cancer Progress Report 2014 ( 1). The approval of
ibrutinib for Waldenström macroglobulinemia was based
on the results of a clinical trial showing that the agent
transformed the lives of many patients ( 94), like Shelley
Lehrman (who was featured in the AACR Cancer Progress
Report 2014; see Ref. 1).
u.s. adults are diagnosed with
Waldenström macroglobulinemia each year.